| Literature DB >> 32867226 |
Nivedita Pavithran1, Harish Kumar2, Arun Somasekharan Menon2, Gopala Krishna Pillai3, Karimassery Ramaiyer Sundaram4, Omorogieva Ojo5.
Abstract
Background: Inflammation is considered as a predictor of cardiovascular diseases in type 2 diabetes mellitus. No previous studies have investigated the effect of low glycemic index (LGI) recipes of South Indian cuisine on the risk factors of cardiovascular disease in patients with diabetes. Aim: The aim of this randomized controlled trial was to evaluate the improvement in cardiovascular risk factors and blood glucose control, in patients with type 2 diabetes, after intervention with recipes of Kerala cuisine, from locally available whole grain cereals, low in glycemic index. Method: This was a prospective and randomized controlled study that was conducted over a period of 24 weeks. A total of 80 participants were recruited from the Department of Endocrinology and Diabetes Outpatient in Kerala, South India. All 80 patients had type 2 diabetes, and were aged between 35 and 65 years. Participants were randomly assigned and advised to follow either a LGI diet plan (n = 40) or their usual diet, which served as a control group (n = 40). The advice was reinforced throughout the study period. Anthropometric, biochemical parameters which included glycemic and cardio-metabolic parameters were measured according to standard procedures. T-tests were conducted to compare the differences between intervention and control groups, and the Pearson correlation coefficient was used to evaluate associations between the variables.Entities:
Keywords: ApoB; HOMA-IR; glycemic control; hs-CRP; low GI diet; south Indian (Kerala) cuisine
Mesh:
Substances:
Year: 2020 PMID: 32867226 PMCID: PMC7504299 DOI: 10.3390/ijerph17176232
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
The diet plan for the low glycemic index (LGI) diet group.
| Breakfast | Red rice puttu (GI = 38) |
| Lunch | Rose Matta rice (GI = 38) |
| Dinner | Broken wheat (GI = 41) upma |
Demographics of the study participants.
| LGI ( | Control ( | |
|---|---|---|
| Age | 54.43 ± 7.57 | 51.93 ± 7.43 |
|
| ||
| Male | 25 (62.5%) | 27 (67.5%) |
| Female | 15 (37.5%) | 13 (32.5%) |
|
| ||
|
| ||
| Yes | 4 (10%) | 3 (7.5%) |
| No | 36 (90%) | 37 (92.5%) |
|
| ||
| Sedentary | 6 (15%) | 4 (10%) |
| Mild | 21 (52.5%) | 25 (62.5%) |
| Moderate | 13 (32.5%) | 11 (27.5%) |
|
| ||
| DLP | 22 (55%) | 25 (62.5%) |
| HTN | 23 (57.5%) | 23 (57.5%) |
| CAD | 11 (27.5%) | 6 (15%) |
| Thyroid | 5 (12.5%) | 2 (5%) |
DLP, dyslipidemia; HTN, hypertension; CAD, coronary artery disease.
Comparison of the baseline characteristics of the study subjects.
| Variable | LGI Group ( | Control Group ( | |
|---|---|---|---|
| Blood Pressure | |||
| Systolic BP (mm Hg) | 132.9 ± 15.37 | 131.10 ± 13.28 | 0.577 |
| Diastolic BP (mm Hg) | 79.90 ± 12.32 | 81.35 ± 8.45 | 0.541 |
| Anthropometric measurement | |||
| Height (cm) | 161.46 ± 7.51 | 163.98 ± 6.69 | 0.118 |
| Weight (kg) | 69.12 ± 10.78 | 72.26 ± 10.52 | 0.191 |
| BMI (kg/m2) | 26.40 ± 3.03 | 26.75 ± 3.29 | 0.623 |
| Waist circumference (cm) | 95.34 ± 8.92 | 96.29 ± 8.99 | 0.631 |
| Biochemical variables | |||
| FBS (mg/dL) | 155.46 ± 36.10 | 150.01 ± 48.65 | 0.571 |
| PPBS (mg/dL) | 227.21 ± 43.18 | 223.17 ± 48.53 | 0.695 |
| HbA1c (%) | 8.44 ± 0.96 | 8.27 ± 0.99 | 0.443 |
| Insulin (mIU/L) | 31.70 ± 46.61 | 28.65 ± 58.38 | 0.796 |
| HOMA-IR | 11.62 ± 14.63 | 8.99 ± 13.61 | 0.408 |
| Total cholesterol (mg/dL) | 172.43 ± 34.84 | 163.42 ± 41.76 | 0.298 |
| Triglycerides (mg/dL) | 147.54 ± 63.20 | 131.30 ± 42.96 | 0.183 |
| HDL (mg/dL) | 42.48 ± 10.12 | 41.82 ± 10.48 | 0.775 |
| LDL (mg/dL) | 119.60 ± 32.13 | 104.50 ± 34.99 | 0.048 * |
| VLDL (mg/dL) | 27.52 ± 10.75 | 27.95 ± 12.87 | 0.872 |
| hsCRP (mg/L) | 3.38 ± 3.83 | 2.79 ± 4.20 | 0.517 |
| ApoB (mg/dL) | 94.44 ± 22.81 | 88.14 ± 24.61 | 0.239 |
| Nutrient intake | |||
| Calories | 1554.8 ± 233.25 | 1430.4 ± 182 | 0.010 ** |
| Carbohydrate (%) | 15.71 ± 2.44 | 15.75 ± 2.09 | 0.940 |
| Protein (%) | 64.62 ± 5.56 | 63.30 ± 6 | 0.313 |
| Fat (%) | 22.6 ± 5.88 | 24.3 ± 5.37 | 0.181 |
| Medications | |||
| Sulfonylureas | 24 | 28 | |
| Metformin | 33 | 42 | |
| DPP4-inh | 15 | 20 | |
| Insulin | 13 | 17 | |
| Acarbose | 2 | 0 | |
| Meglitinides (Repaglinide) | 1 | 0 | |
| Statins | 20 | 26 | |
| Antihypertensives | 22 | 20 |
Notes: BP, blood pressure; BMI, body mass index; FBS, fasting blood sugar; PPBS, postprandial blood sugar; HbA1c, glycated hemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; hsCRP, high sensitivity C-reactive protein; ApoB, apolipoprotein-B. * (p < 0.05); ** (p < 0.01)
Comparison of mean ± SD of the variables at baseline and 24 weeks after intervention between groups.
| Variable | Group | Baseline | 24 Weeks | Mean Difference | ||
|---|---|---|---|---|---|---|
| Blood Pressure | ||||||
| Systolic pressure (mmHg) | LGI | 132.90 ± 15.32 | 130.35 ± 17.63 | −2.55 ± 16.6 | 0.337 | 0.683 |
| Control | 131.1 ± 13.28 | 131.83 ± 14.43 | 0.72 ± 14.84 | 0.759 | ||
| Diastolic pressure (mmHg) | LGI | 79.9 ± 12.32 | 77.63 ± 7.08 | −2.27 ± 12.67 | 0.263 | 0.068 |
| Control | 81.35 ± 8.45 | 80.60 ± 7.29 | −0.75 ± 6.96 | 0.500 | ||
| Anthropometric measurements | ||||||
| Weight (kg) | LGI | 69.12 ± 10.78 | 67.25 ± 9.81 | −1.87 ± 2.63 | 0.000 ** | 0.020 * |
| Control | 72.26 ± 10.52 | 72.79 ± 11.00 | 0.53 ± 1.96 | 0.094 | ||
| BMI (kg/m2) | LGI | 26.40 ± 3.03 | 25.71 ± 2.77 | −0.70 ± 0.99 | 0.000 ** | 0.078 |
| Control | 26.75 ± 3.29 | 26.95 ± 3.42 | 0.20 ± 0.70 | 0.083 | ||
| Waist circumference (cm) | LGI | 95.34 ± 8.92 | 92.40 ± 8.99 | −2.94 ± 4.71 | 0.000 ** | 0.148 |
| Control | 96.29 ± 8.99 | 95.45 ± 9.64 | −0.84 ± 4.47 | 0.244 | ||
| Biochemical parameters | ||||||
| FBS (mg/dL) | LGI | 155.46 ± 36.10 | 136.75 ± 27.54 | −21.21 ± 39.42 | 0.001 ** | 0.192 |
| Control | 150.01 ± 48.65 | 146.63 ± 38.73 | −3.38 ± 34.57 | 0.540 | ||
| PPBS (mg/dL) | LGI | 227.21 ± 43.18 | 189.33 ± 56.49 | −37.87 ± 59.36 | 0.000 ** | 0.063 |
| Control | 223.17 ± 48.53 | 212.22 ± 52.13 | −10.94 ± 51.44 | 0.186 | ||
| HbA1c (%) | LGI | 8.44 ± 0.96 | 7.52 ± 0.94 | −0.93 ± 0.92 | 0.000 ** | 0.003 ** |
| Control | 8.27 ± 0.99 | 8.27 ± 1.20 | 0.012 ± 0.87 | 0.929 | ||
| Insulin (mIU/L) | LGI | 31.70 ± 46.61 | 14.79 ± 15.89 | −16.91 ± 40.42 | 0.012 * | 0.030 * |
| Control | 28.65 ± 58.38 | 33.57 ± 51.17 | 4.92 ± 57.67 | 0.592 | ||
| HOMA-IR | LGI | 11.62 ± 14.63 | 5.10 ± 6.06 | −6.51 ± 12.11 | 0.002 ** | 0.017 * |
| Control | 8.99 ± 13.61 | 10.83 ± 13.50 | 1.84 ± 15.76 | 0.464 | ||
| Total Cholesterol (mg/dL) | LGI | 172.43 ± 34.84 | 159.12 ± 33.68 | −13.30 ± 37.37 | 0.030 * | 0.422 |
| Control | 163.42 ± 41.76 | 152.97 ± 34.41 | −10.45 ± 31.77 | 0.044 * | ||
| Triglycerides (mg/dL) | LGI | 147.54 ± 63.20 | 120.65 ± 44.80 | −26.89 ± 48.37 | 0.001 ** | 0.025 * |
| Control | 131.30 ± 42.96 | 153.06 ± 77.60 | 21.76 ± 56.69 | 0.020 * | ||
| HDL (mg/dL) | LGI | 42.48 ± 10.12 | 41.92 ± 11.22 | −0.56 ± 5.64 | 0.531 | 0.886 |
| Control | 41.82 ± 10.48 | 42.27 ± 10.50 | 0.44 ± 6.86 | 0.683 | ||
| LDL (mg/dL) | LGI | 119.60 ± 32.13 | 105.02 ± 26.80 | −14.57 ± 27.42 | 0.002 ** | 0.979 |
| Control | 104.50 ± 34.99 | 104.85 ± 33.13 | 0.34 ± 28.44 | 0.939 | ||
| VLDL (mg/dL) | LGI | 27.52 ± 10.75 | 25.62 ± 11.24 | −1.90 ± 10.28 | 0.249 | 0.254 |
| Control | 27.95 ± 12.87 | 28.79 ± 13.34 | 0.84 ± 9.71 | 0.588 | ||
| hs-CRP (mg/L) | LGI | 3.38 ± 3.83 | 1.46 ± 1.04 | −1.92 ± 3.83 | 0.003 ** | 0.026 * |
| Control | 2.79 ± 4.20 | 3.16 ± 4.61 | 0.36 ± 3.21 | 0.479 | ||
| ApoB (mg/dL) | LGI | 94.44 ± 22.81 | 81.88 ± 19.83 | −12.55 ± 19.50 | 0.000 ** | 0.007 ** |
| Control | 88.14 ± 24.61 | 95.05 ± 22.27 | 6.90 ± 16.15 | 0.010 ** | ||
| Nutrient intake | ||||||
| Calories (kcal) | LGI | 1430.4 ± 182 | 1511 ± 137.5 | 80.6 ± 243 | 0.043 * | 0.010 ** |
| Control | 1554.8 ± 233.3 | 1450.4 ± 157.1 | 104.4 ± 250.1 | 0.012 | ||
| Protein (g) | LGI | 55.8 ± 8.49 | 61.8 ± 10.1 | 6.02 ± 14.95 | 0.015 * | 0.025 * |
| Control | 61.3 ± 12.8 | 58.5 ± 11.7 | −2.88 ± 8.15 | 0.221 | ||
| Carbohydrate (g) | LGI | 230.9 ± 33.9 | 232.7 ± 28.4 | 1.85 ± 47.11 | 0.807 | 0.081 |
| Control | 245.1 ± 37.5 | 238.4 ± 26.4 | −6.69 ± 46.2 | 0.365 | ||
| Fat (g) | LGI | 36.1 ± 10.4 | 40.9 ± 7.71 | 1.77 ± 7.47 | 0.036 * | 0.019 * |
| Control | 42.4 ± 12.7 | 34.2 ± 10.1 | −8.15 ± 17.2 | 0.005 ** |
BMI, body mass index; FBS, fasting blood sugar; PPBS, postprandial blood sugar; HbA1c, glycated hemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; hsCRP, high sensitivity C-reactive protein; ApoB, apolipoprotein-B. * (p < 0.05); ** (p < 0.01)
Comparison of the percentage of the macronutrient intake between baseline and 24 weeks after dietary intervention in the study groups.
| Nutrient Intake | Baseline | 24 Weeks | ||
|---|---|---|---|---|
| Calories (kcal) | LGI | 1430.4 ± 182 | 1511 ± 137.5 | 0.07 |
| Control | 1554.8 ± 233.3 | 1450.4 ± 157.1 | ||
| Protein (%) | LGI | 15.71 ± 2.44 | 16.38 ± 2.44 | 0.571 |
| Control | 15.75 ± 2.09 | 16.07 ± 2.53 | ||
| Carbohydrate (%) | LGI | 64.62 ± 5.56 | 61.6 ± 4.62 | <0.001 ** |
| Control | 63.3 ± 6 | 65.93 ± 5.14 | ||
| Fat (%) | LGI | 22.6 ± 5.88 | 24.37 ± 3.9 | 0.003 ** |
| Control | 24.3 ± 5.37 | 21.12 ± 5.4 |
** (p < 0.01)
Figure 1(a)—The mean difference in the anthropometric measurements; (b)—biochemical variables—blood glucose levels and insulin resistance; and (c)—lipid profile and cardiovascular biomarkers after a 24-week diet intervention between the groups. BMI, body mass index; FBS, fasting blood sugar; PPBS, postprandial blood sugar; HbA1c, glycated hemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; hsCRP, high sensitivity C-reactive protein; ApoB, apolipoprotein-B; LGI, low glycemic Index. * Denotes significant difference.
Figure 2Correlation of weight with anthropometric and biochemical parameters: (a) The correlation of weight with WC (waist circumference); (b) PPBS (postprandial blood sugar); (c) HbA1c after 24 weeks of dietary intervention. (d) Correlation of apolipoprotein B with fasting insulin after 24 weeks of dietary intervention.
Correlation between weight and other study variables after 24 weeks of diet intervention.
| Weight | |||
|---|---|---|---|
| Pearson Correlation Coefficient (r) | |||
| Waist circumference | 0.735 ** | <0.01 | |
| Postprandial blood sugar | 0.251 * | <0.05 | |
| HbA1c | 0.241 * | <0.05 | |
* (p < 0.05); ** (p < 0.01).
Correlation between apolipoprotein-B and other study variables after 24 weeks of diet intervention.
| Variables | ApoB | |
|---|---|---|
| Pearson Correlation Coefficient (r) | ||
| Total Cholesterol | 0.529 ** | <0.01 |
| Triglycerides | 0.314 ** | <0.01 |
| LDL | 0.599 ** | <0.01 |
| Fasting Insulin | 0.237 * | <0.05 |
* (p < 0.05); ** (p < 0.01).